Triglycerides: The Body's Main Energy-Carrying Fats
Triglycerides blood testing measures the amount of triglycerides—the body’s main storage form of fat—in your bloodstream. A triglyceride is a small energy package built from one glycerol backbone and three fatty acids (triacylglycerol). Triglycerides come from two places: they’re absorbed from food by the intestine and they’re made by the liver, especially from excess sugars. In the blood, they travel inside fat-carrying particles (lipoproteins): chylomicrons after a meal, and very-low-density lipoproteins (VLDL) from the liver.
This biomarker captures how your body stores and moves fuel. Triglycerides deliver fatty acids to muscles and the heart for energy and to fat tissue for storage, a process governed by enzymes that unload them from lipoproteins (lipoprotein lipase). The measured level reflects the balance between input from the gut and liver and clearance by tissues—essentially, how efficiently you handle and traffic energy from fats and sugars (lipid and carbohydrate metabolism).
Why Triglycerides Sit at the Crossroads of Metabolism
Triglycerides are the bloodstream’s main energy-carrying fats, packaged in particles from the gut and liver. They reflect how your intestine absorbs fat, how your liver handles surplus fuel, and how hormones like insulin direct energy between fat, muscle, and pancreas. Because they sit at the crossroads of metabolism, they signal risk across the heart, liver, and endocrine systems.
Big picture: triglycerides integrate gut, liver, adipose, and pancreatic signaling. Persistently high levels track with atherosclerotic risk, fatty liver, and future diabetes, while very high levels raise pancreatitis risk.
How a Triglyceride Value Reads From Optimal to Severe
Typical reference points: under 150 is desirable, 150–199 borderline, 200–499 high, and 500 or higher very high. For most people, within reference ranges sits toward the lower end of normal—not extremely low.
When values are unusually low, they often mirror limited fat intake or absorption, an overactive thyroid, chronic illness, or rare genetic patterns. The physiology is less fuel in circulation and fewer triglyceride-rich particles, which can coincide with poor delivery of fat-soluble vitamins; people may notice dry skin, night-vision changes, easy bruising, or muscle weakness if malabsorption is present. In children, very low levels can suggest undernutrition. During pregnancy, triglycerides normally rise, so low values are uncommon.
When values are elevated, the liver is typically overproducing VLDL under insulin resistance, or particles are not cleared well. This promotes remnant cholesterol, small dense LDL, low HDL, and fat buildup in the liver. Most people feel nothing; very high levels can cause abdominal pain from pancreatitis, eruptive skin bumps, and milky blood. Men with visceral fat and women after menopause often see higher levels; pregnancy drives a late-gestation rise, and genetic disorders may present in childhood.
What Distorts a Triglyceride Measurement
Notes: Interpretation depends on fasting versus nonfasting sampling, recent meals or alcohol, acute illness, and pregnancy timing. Age and sex shift typical values, with men and postmenopausal women tending higher. Assay and day‑to‑day biologic variability exist; reference intervals may differ across labs.
What a Triglyceride Result Adds to Cardiometabolic Risk
A triglycerides blood test measures the amount of triglyceride-rich lipoproteins (mainly VLDL and chylomicrons) in blood. Triglycerides carry energy from liver and gut to tissues. Levels reflect how you process sugars and fats and relate to cardiometabolic risk, fatty liver, and, at extremes, pancreatitis. They influence vessel health and energy delivery to muscle and brain.
Low values usually reflect reduced production or faster clearance of these particles. Causes include low energy intake or malabsorption, overactive thyroid (hyperthyroidism), chronic illness, and rare genetic ApoB disorders. System-wise this can signal limited circulating fuel and, in genetic forms, impaired transport of fat‑soluble vitamins. Pregnancy usually raises levels.
Being in range suggests balanced hepatic output and peripheral use of triglycerides, good insulin sensitivity, and vascular stability. Within the usual reference range, lower values are generally associated with lower cardiometabolic risk, especially on fasting measurements.
High values usually reflect excess liver export of VLDL or reduced tissue breakdown. Common drivers include insulin resistance or diabetes, too little thyroid hormone (hypothyroidism), kidney disease, alcohol, and drugs such as estrogens, steroids, some beta‑blockers, and retinoids. Genetic conditions and late pregnancy raise levels. System effects include atherogenic dyslipidemia, fatty liver, and pancreatitis risk when very high.
FAQs
Triglycerides testing measures the concentration of triglycerides in your blood to assess cardiometabolic and liver-related risk.
Testing helps identify atherosclerotic cardiovascular risk, pancreatitis risk at very high levels, insulin-resistant patterns, fatty liver risk, and secondary causes influenced by diet, alcohol, thyroid, kidney function, or medications.
Regular testing helps track response to lifestyle changes and therapies. Frequency depends on personal goals and risk factors; many people retest periodically to monitor trends.
Diet high in added sugars and refined starches, alcohol, weight gain, inactivity, insulin resistance, hypothyroidism, chronic kidney disease, and certain medications can raise levels. Increased activity, fiber, unsaturated fats, and omega-3s can lower them.
Fasting can improve comparability across tests, especially if you are monitoring change. Non-fasting measurements still provide meaningful risk information; follow the instructions provided with your test.
Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.
We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.
References
- Feingold, K. R. (2024). Introduction to lipids and lipoproteins. In Endotext. MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK305896/
- Nordestgaard, B. G. (2016). Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: New insights from epidemiology, genetics, and biology. Circulation Research, 118(4), 547-563. https://doi.org/10.1161/CIRCRESAHA.115.306249
- Nordestgaard, B. G., Langsted, A., Mora, S., Kolovou, G., Baum, H., Bruckert, E., Watts, G. F., Sypniewska, G., Wiklund, O., Borén, J., Chapman, M. J., Cobbaert, C., Descamps, O. S., von Eckardstein, A., Kamstrup, P. R., Pulkki, K., Kronenberg, F., Remaley, A. T., Rifai, N., ... Langlois, M. (2016). Fasting is not routinely required for determination of a lipid profile: Clinical and laboratory implications including flagging at desirable concentration cut-points—A joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. European Heart Journal, 37(25), 1944-1958. https://doi.org/10.1093/eurheartj/ehw152
- Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., Goldberg, R., Heidenreich, P. A., Hlatky, M. A., Jones, D. W., Lloyd-Jones, D., Lopez-Pajares, N., Ndumele, C. E., Orringer, C. E., Peralta, C. A., ... Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation, 139(25), e1082-e1143. https://doi.org/10.1161/CIR.0000000000000625
- Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., Graham, I. M., Halliday, A., Landmesser, U., Mihaylova, B., Pedersen, T. R., Riccardi, G., Richter, D. J., Sabatine, M. S., Taskinen, M. R., ... Wiklund, O. (2020). 2019 ESC/EAS guidelines for the management of dyslipidaemias. European Heart Journal, 41(1), 111-188. https://doi.org/10.1093/eurheartj/ehz455






































.avif)
